



(51) International Patent Classification:

A61K 31/454 (2006.01) A61P 25/08 (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2024/061589

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/612,997	20 December 2023 (20.12.2023)	US
63/612,998	20 December 2023 (20.12.2023)	US
63/691,887	06 September 2024 (06.09.2024)	US
63/691,900	06 September 2024 (06.09.2024)	US

(71) Applicant: **GRIN THERAPEUTICS, INC.** [US/US]; 230 Park Avenue, Suite 2830, New York, New York 10169 (US).

(72) Inventors: **MUGLIA, Pierandrea**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US). **LEUCHTER, Bruce**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US).

apeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US). **CHRISTINGER, Hans**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US). **PANZARA, Michael**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US). **BANI, Massimo**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US). **PAULSON, Susan**; c/o GRIN Therapeutics, Inc., 230 Park Avenue, Suite 2830, New York, New York 10169 (US).

(74) Agent: **MCCARTY, Catherine M.** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITIONS COMPRISING RADIPRODIL AND THE USE OF RADIPRODIL IN THE TREATMENT OF EPILEPTIC OR NEUROBEHAVIORAL DISORDERS




FIG. 1

(57) Abstract: The present disclosure provides, in part, methods of treating an epileptic disorder in a pediatric subject in need thereof, comprising administering radiprodil to the pediatric subject; pharmaceutical compositions comprising radiprodil and pharmaceutically acceptable excipients and methods of use thereof in the treatment of disorders such as epileptic disorders.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

- (88) Date of publication of the international search report:**
21 August 2025 (21.08.2025)